Nymox Pharmaceutical Corporation (NYMXF)
OTCMKTS · Delayed Price · Currency is USD
0.0553
-0.0120 (-17.83%)
Aug 20, 2025, 11:10 AM EDT
Nymox Pharmaceutical Company Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population.
Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma.
The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure.
In addition, it develops drugs for the treatment and prevention of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Nymox Pharmaceutical Corporation
| Country | Bahamas |
| Founded | 1989 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Paul Averback |
Contact Details
Address: Bay & Deveaux Streets Nassau Bahamas | |
| Phone | 800 936 9669 |
| Website | nymox.com |
Stock Details
| Ticker Symbol | NYMXF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | BSP733981026 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Averback DABP, M.D. | Founder, Chairman, Chief Executive Officer and President |
| Lin Dodd | QA and Compliance Manager |
| Patrick A. Doody | Vice President, General Counsel and Director |